Categories: News

Genetic Leap and Lilly Enter Collaboration to Accelerate Genetic Medicine Development with AI

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

— Collaboration to leverage Genetic Leap’s RNA-targeted AI platform to generate genetic medicines against selected targets

— Genetic Leap to receive up to $409 million in upfront and milestone payments as well as tiered royalties

NEW YORK, Sept. 5, 2024 /PRNewswire/ — Genetic Leap, an AI-native techbio company innovating at the cutting edge of Artificial Intelligence and RNA genetic medicine, today announced a research collaboration with Eli Lilly and Company to develop genetic medicine therapeutics.

The collaboration builds on a successful pilot between the two companies and will leverage Genetic Leap’s RNA-targeted AI platform to generate oligonucleotide drugs against targets selected by Lilly in high priority therapeutic areas. The central role of RNA in orchestrating essential biological processes holds significant potential to address critical diseases that traditional drugs have not been able to target effectively. Historically, drugging RNA has presented tremendous challenges. Genetic Leap’s proprietary AI platform is revolutionizing the approach to drugging RNA.

“We are thrilled to collaborate with Lilly and deeply share their strong commitment to developing RNA medicines,” said Dr. Bertrand Adanve, CEO and founder of Genetic Leap. “Our primary goal in building the Genetic Leap AI platform is to accelerate the development of life-saving medicines for patients, and this collaboration with Lilly’s talented and savvy R&D team takes us significantly closer to that goal.”

Under the terms of the agreement, Genetic Leap will receive from Lilly up to $409 million in upfront, development, clinical, regulatory, and commercial milestone payments, in addition to tiered royalties.

About Genetic Leap
Genetic Leap is innovating at the cutting edge of AI and RNA genetic medicine to redefine drug development and more quickly address the health needs of millions of people. Genetic Leap is advancing a pipeline that spans internal as well as partnered programs, across both novel and established (but traditionally undruggable) disease targets. For more information, please visit www.genetic-leap.com. You can also follow us on LinkedIn.

For Media inquiries:
press@genetic-leap.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genetic-leap-and-lilly-enter-collaboration-to-accelerate-genetic-medicine-development-with-ai-302239471.html

SOURCE Genetic Leap

Staff

Recent Posts

Freeze Drying Equipment Market to Surge from USD 4.9 Billion to USD 8.4 Billion by 2032 – Meticulous Research®

Lyophilization Process Innovation, Food Preservation Demand, and Pharmaceutical Industry Expansion Drive 7.9% CAGR Growth Across…

2 hours ago

Texas Centers for Infectious Disease Associates Notifies Individuals of Data Security Incident

FORT WORTH, Texas, June 27, 2025 /PRNewswire/ -- Texas Centers for Infectious Disease Associates ("TCIDA")…

2 hours ago

Dogtopia’s Redesigned Wellness App Drives Convenience and Engagement for Parents, Activity and Exercise Tracking for Dogs

PHOENIX, June 27, 2025 /PRNewswire/ -- Dogtopia, the nation's largest and fastest-growing pet wellness franchise, has…

8 hours ago

Patient Advocate Foundation Praises SCOTUS Decision Upholding Preventative Care Provision in Affordable Care Act

HAMPTON, Va., June 27, 2025 /PRNewswire/ -- Patient Advocate Foundation (PAF), a national non-profit charity…

8 hours ago

Pinnacle Fertility Appoints Dr. Richard Scott to Board of Directors, Signaling Leap Forward in Scientific and Strategic Excellence

SCOTTSDALE, Ariz., June 27, 2025 /PRNewswire/ -- Pinnacle Fertility proudly announces the appointment of Dr.…

8 hours ago

Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch

Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a…

14 hours ago